Skip to main content

Table 1 Clinical information of subjects

From: Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma

Subject No. Age ranges (years) PSa Histological type Primary lesion Sum of diameter of target lesions (mm)b Time from initial diagnosis to enrolled date (months) Time to progression in prior systemic chemotherapy (months)
Site At baseline
Trabectedin group
1 50- < 60 0 EMCS lower limbs resected 132.8 94.2 8.7 (IE)
2 60- < 70 1 EMCS lower limbs resected 38.4 4.3 1.1 (doxorubicin)
3 <40 0 MCS neck conserved 11.3 63.0 NA (neoadjuvant chemotherapy)
4 <40 1 MCS basal meninges resected 162.3 82.6 3.7 (doxorubicin)
5 <40 1 MCS neck resected 57.3 145.6 NA (neoadjuvant chemotherapy)
Best supportive care group
6 <40 1 MCS face conserved 136.8 116.2 7.0 (doxorubicin and cisplatin)
7 <40 0 MCS pleura resected 94.6 2.5 0.7 (VDC)
8 <40 1 MCS retroperi-toneum resected 209.3 13.4 NA (neoadjuvant chemotherapy)
  1. MCS Mesenchymal chondrosarcoma, EMCS Extraskeletal myxoid chondrosarcoma, PS performance status, NA not applicable, IE ifosfamide and etoposide, VDC vincristine, doxorubicin and cyclophosphamide
  2. aEastern Cooperative Oncology Group (ECOG) performance status
  3. bAssessed by central radiology imaging review